In Defense of Global Capitalism

Canada's Competition Tribunal fails Canadians once again, prioritizes telecom oligopoly amidst threat of economic recession

Retrieved on: 
Friday, December 30, 2022

Anyone familiar with the Canadian telecom industry is aware that allowing Rogers to acquire Shaw will lead to even greater industry concentration, lessened competition, and, ultimately, even higher prices for Canadians.

Key Points: 
  • Anyone familiar with the Canadian telecom industry is aware that allowing Rogers to acquire Shaw will lead to even greater industry concentration, lessened competition, and, ultimately, even higher prices for Canadians.
  • Many of these experts have been consistently outspoken about the blatant issues of this merger and the subsequent impact it will have on Canadians from coast-to-coast.
  • Globalive Capital manages Globalive's diversified investment portfolio across multiple asset classes including venture, private equity, real estate, and infrastructure.
  • Globalive Ventures has made over 125 early-stage technology venture investments and is well-known as a strategic, entrepreneur friendly investor.

Key takeaway from Rogers-Shaw evidentiary hearings: the deck is stacked against Canadians, unless Minister Champagne acts

Retrieved on: 
Thursday, December 1, 2022

Also made clear is that even as Canadian consumers suffer, wealthy executives stand to become even richer on the backs of this anticompetitive transaction.

Key Points: 
  • Also made clear is that even as Canadian consumers suffer, wealthy executives stand to become even richer on the backs of this anticompetitive transaction.
  • There can be no doubt that these bonuses reflect the true incentives of Rogers and Shaw.
  • It will be up to Minister Champagne to stand with his Commissioner, and on the side of Canadians, to prevent this merger from proceeding.
  • Globalive Media focuses on the innovation ecosystem and produces the show Beyond Innovation ( beyondinnovation.tv ) that airs globally on the Bloomberg platform.

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

Retrieved on: 
Thursday, December 1, 2022

Currently, there is no Food and Drug Administration (FDA) approved drug for treating agitation in dementia related to Alzheimers (Jones et al., 2021).

Key Points: 
  • Currently, there is no Food and Drug Administration (FDA) approved drug for treating agitation in dementia related to Alzheimers (Jones et al., 2021).
  • We believe that IGC-AD1 has the potential to revolutionize the treatment of Alzheimers Disease as the first and only low-dose natural THC-based formulation candidate currently undergoing FDA trials, commented Ram Mukunda, CEO of IGC.
  • Through these and further trials, we look forward to establishing IGC-AD1s efficacy in treating the symptoms related to Alzheimers Disease.
  • IGC-AD1 relies on low-doses of THC, a psychoactive cannabinoid, and another compound as active agents in trials for Alzheimers.

CTO Forum has appointed Marinela Tudoran, Global Head of Investment Bank Technology at Credit Suisse to the CTO Forum Advisory Board

Retrieved on: 
Tuesday, November 15, 2022

SANTA CLARA, Calif., Nov. 15, 2022 /PRNewswire-PRWeb/ -- The CTO Forum is pleased to announce that Marinela Tudoran, Managing Director and Global Head of Investment Bank Technology at Credit Suisse, has been appointed to the CTO Forum Advisory Board. The CTO Forum brings together senior technology executives, business leaders, and top academicians to discuss and collaborate on key technology issues and to accelerate innovation across organizations.

Key Points: 
  • CTO Forum has appointed Marinela Tudoran, Global Head of Investment Bank Technology at Credit Suisse to the CTO Forum Advisory Board.
  • SANTA CLARA, Calif., Nov. 15, 2022 /PRNewswire-PRWeb/ -- The CTO Forum is pleased to announce that Marinela Tudoran, Managing Director and Global Head of Investment Bank Technology at Credit Suisse, has been appointed to the CTO Forum Advisory Board.
  • I am certain that Marinela's contributions will provide tangible, lasting benefit to the CTO Forum community," stated Basheer Janjua, CTO Forum Founding Chair and President.
  • In 2022, through the concerted efforts of the dedicated Advisory Board, CTO Forum has introduced RETHINK DIGITAL: Emergent Technologies Accelerating Digital Transformation.

Marinela Tudoran, Global Head of Investment Bank Technology at Credit Suisse has been appointed to the CTO Forum Advisory Board

Retrieved on: 
Monday, November 7, 2022

SANTA CLARA, Calif., Nov 7, 2022 /PRNewswire-PRWeb/ -- The CTO Forum is pleased to announce that Marinela Tudoran, Managing Director and Global Head of Investment Bank Technology at Credit Suisse has been appointed to the CTO Forum Advisory Board. The CTO Forum brings together senior technology executives, business leaders, and academicians to discuss and collaborate on key technology issues and to accelerate innovation across organizations.

Key Points: 
  • The CTO Forum today announced that Marinela Tudoran, Managing Director and Global Head of Investment Bank Technology at Credit Suisse has been appointed to the CTO Forum Advisory Board.
  • SANTA CLARA, Calif., Nov 7, 2022 /PRNewswire-PRWeb/ -- The CTO Forum is pleased to announce that Marinela Tudoran, Managing Director and Global Head of Investment Bank Technology at Credit Suisse has been appointed to the CTO Forum Advisory Board.
  • The CTO Forum brings together senior technology executives, business leaders, and academicians to discuss and collaborate on key technology issues and to accelerate innovation across organizations.
  • I am certain that Marinela's contributions will provide tangible, lasting benefit to the CTO Forum community," stated Basheer Janjua, CTO Forum Founding Chair, and President.

IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022

Retrieved on: 
Tuesday, November 1, 2022

India Globalization Capital, Inc. (NYSE American: IGC) (IGC or the Company) today reported its second fiscal quarter 2023 financial results.

Key Points: 
  • India Globalization Capital, Inc. (NYSE American: IGC) (IGC or the Company) today reported its second fiscal quarter 2023 financial results.
  • Sales of the Companys CBD-infused products and services increased about 345% for the six-months ended September 30, 2022 compared to the six-months ended September 30, 2021.
  • Revenue was approximately $202,000 for the three months ended Sept. 30, 2022, compared to $56,000 for the three months ended Sept. 30, 2021.
  • Research and Development (R&D) expenses were $768,000 for the three months ended Sept. 30, 2022, compared to approximately $276,000 for the three months ended Sept. 30, 2021.

IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC

Retrieved on: 
Wednesday, September 21, 2022

India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (USPTO) issued a second patent (#11,446,276) for the treatment of Alzheimers disease entitled Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimers disease.

Key Points: 
  • India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (USPTO) issued a second patent (#11,446,276) for the treatment of Alzheimers disease entitled Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimers disease.
  • The original patent application was initiated by the University of South Florida (USF) and filed on July 30, 2015.
  • On May 25, 2017, IGC entered into an exclusive license agreement with USF with respect to the patent application and the associated research conducted on Alzheimers disease.
  • Separately, on July 22, 2021, IGC announced the grant of the first patent (11,065,225) for some of that research and work.

IGC Reports Financial Results for the Quarter Ended June 30, 2022

Retrieved on: 
Monday, August 8, 2022

India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Companys 2023 fiscal year.

Key Points: 
  • India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Companys 2023 fiscal year.
  • On June 7, 2022, the USPTO issued a patent (#11,351,152) to the Company titled Method and Composition for Treating Seizure Disorders.
  • Revenue was approximately $212 thousand and $77 thousand for the three months ended June 30, 2022, and June 30, 2021, respectively.
  • Research and Development (R&D) expenses were $1.4 million during the three months ended June 30, 2022, and approximately $444 thousand for the three-month ended June 30, 2021.

IGC Reports Financial Results for Fiscal Year Ended March 31, 2022

Retrieved on: 
Thursday, June 23, 2022

India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) announces its financial results for Fiscal Year Ended March 31, 2022.

Key Points: 
  • India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) announces its financial results for Fiscal Year Ended March 31, 2022.
  • Revenue was approximately $397 thousand and $898 thousand for Fiscal 2022 and Fiscal 2021, respectively.
  • SG&A expenses increased by approximately $5.3 million or 68% to $13.2 million for Fiscal 2022, from approximately $7.9 million for Fiscal 2021.
  • The R&D expenses increased by approximately $1.4 million or 151% to $2.3 million in Fiscal 2022, from approximately $929 thousand for Fiscal 2021.

IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate

Retrieved on: 
Tuesday, June 21, 2022

India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimers drug development candidate.

Key Points: 
  • India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimers drug development candidate.
  • JNCASRs research based on Alzheimers cell lines, identified one lead NMI molecule, TGR 63, with the potential to reduce beta amyloid (A) plaques.
  • IGC acquired exclusive global rights to the molecule and plans to develop this NMI lead candidate further.
  • IGC is currently in human trials with IGC-AD1 that targets neuropsychiatric symptoms associated with dementia in Alzheimers.